Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Liquidia (Nasdaq:LQDA) announced that CEO Dr. Roger Jeffs and COO/CFO Michael Kaseta will discuss the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:45 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia (Nasdaq:LQDA) announced that CEO Dr. Roger Jeffs and COO/CFO Michael Kaseta will discuss the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:45 p.m. ET. The live webcast and a 30-day replay will be available on the company’s investor relations website.
Details
News Market Reaction – LQDA
On May 27, the day this news came out, LQDA closed 3.21% above the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Conference date
- June 3, 2026
- Jefferies Global Healthcare Conference fireside chat
- Presentation time
- 12:45 p.m. ET
- Scheduled time for Liquidia business update
- Webcast archive period
- 30 days
- Replay available on company website
Historical Context
-
Strong Q1 2026 results from YUTREPIA with meaningful profitability.
-
Participation in May 2026 investor conferences with senior management updates.
-
Announcement of timing and webcast for Q1 2026 results.
-
April 2026 investor conferences with one-on-one meetings and webcast.
-
Full-year 2025 results highlighting YUTREPIA sales and mixed profitability.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m. ET.
Access to this event will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the company’s website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
media@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.